SynthesisBMC psychiatry2025
Pomgulated methionil (LY2140023) in schizophrenia patients: a systematic review and meta-analysis.
Synthesis in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antipsychotic Drug Action, Novel Treatment Targets, and the Failure of Current Clinical Trial Designs in Evaluating New Target Molecules.Biological psychiatry · 2026Review
- Glutamate Metabotropic Receptors-Linked Postsynaptic Density Proteins: An Emergent Hub for Antipsychotics' Regulation of Synaptic Plasticity and Metaplasticity.Biomolecules · 2026Review
- Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.Frontiers in psychiatry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPomaglumetad methionil (LY2140023 monohydrate) is a potent and selective agonist for metabotropic glutamate receptors (mGluR2/3). Unlike traditional antipsychotics, it does not directly interact with dopamine or serotonin (5-HT2A) receptors, potentially offering a novel mechanism of action with a different side-effect profile. We aim to provide an overview of this novel drug and evaluate its efficacy in comparison to both placebo and atypical antipsychotics by performing a systematic review and meta-analysis.
methodsA comprehensive literature search was conducted to identify relevant studies. The included studies investigated the effect of Promogulated methionil. The quality of studies was assessed using the Cochrane Risk of Bias 2 (ROB-2) Statistical analysis was conducted using Review Manager (revman) with outcomes expressed as Mean differences (MD) with 95% confidence intervals (CI).
resultsThe systematic review included 4 randomized clinical trials (RCTs). The analysis revealed that pomaglumetad methionil (LY2140023) didn't have a statistically significant effect on PANNS compared to placebo (p-value = 0.31) and it was less effective in decreasing PANSS score in comparison to atypical antipsychotics (p-value < 0.00001). However, the drug showed a significant effect on weight gain (p-value < 0.00001) and prolactin (p < 0.0001) in comparison to atypical antipsychotics.
conclusionsIn conclusion, this systematic review and meta-analysis provide evidence that pomaglumetad methionil (LY2140023) does not demonstrate consistent efficacy in the treatment of schizophrenia. Although the compound is associated with a more favorable profile regarding weight gain and prolactin elevation, these advantages do not compensate for its lack of therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.